// App-Quantinova.ai

TPS2599 : A Phase II Basket Study of the Oral TRK Inhibitor LOXO101 in Adult Subjects with NTRK Fusion-Positive Tumors.

Researchers

Presenter

  • Alexander E. Drilon

Principal Investigators

  • David S. Hong

  • Scott Cruickshank

  • Maegan Deegan

  • Nora Ku

  • David Michael Hyman

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Scott Cruickshank & Associates, Santa Barbara, CA

  • Loxo Oncology, Stamford, CT

Locations

  • United States

Companies

  • Loxo Oncology, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Advanced biliary tract carcinoma

  • Sarcoma

Biomarkers

  • Neurotrophic tropomyosin receptor kinase

  • High affinity nerve growth factor receptor

Drug/Treatment

  • Larotrectinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT02576431

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved